For which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?

Simple item page
dc.catalogadorjlo
dc.contributor.authorRodríguez Martínez, Carlos E.
dc.contributor.authorNino, Gustavo
dc.contributor.authorCastro-Rodriguez, José A.
dc.contributor.authorAcuña-Cordero, Ranniery
dc.contributor.authorSossa-Briceño, Mónica P.
dc.contributor.authorMidulla, Fabio
dc.date.accessioned2024-01-29T17:48:29Z
dc.date.available2024-01-29T17:48:29Z
dc.date.issued2021
dc.description.abstractAlthough there is increasing evidence showing that infants with viral bronchiolitis exhibit a high degree of heterogeneity, a core uncertainty shared by many clinicians is with regard to understanding which patients are most likely to benefit from bronchodilators such as albuterol. Based on our review, we concluded that older infants with rhinovirus (RV) bronchiolitis, especially those with a nasopharyngeal microbiome dominated by Haemophilus influenzae; those affected during nonpeak months or during non-respiratory syncytial virus (RSV) predominant months; those with wheezing at presentation; those with clinical characteristics such as atopic dermatitis or a family history of asthma in a first-degree relative; and those infants infected with RSV genotypes ON1 and BA, have the greatest likelihood of benefiting from albuterol. Presently, this patient profile could serve as the basis for rational albuterol administration in patients with viral bronchiolitis, at least on a therapeutic trial basis, and it could also be the starting point for future targeted randomized clinical trials (RCTs) on the use of albuterol among a subset of infants with bronchiolitis.
dc.fechaingreso.objetodigital2024-04-11
dc.fuente.origenORCID-ene24
dc.identifier.doi10.15586/aei.v49i1.12
dc.identifier.issn0301-0546
dc.identifier.urihttps://europepmc.org/articles/PMC8850933
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/81018
dc.information.autorucEscuela de Medicina; Castro Rodríguez, José Antonio; 0000-0002-0708-4281; 113247
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final10
dc.pagina.inicio1
dc.revistaAllergologia et Immunopathologia
dc.rightsacceso abierto
dc.subjectBronchiolitis
dc.subjectViral bronchiolitis phenotyping
dc.subjectClinical practice guidelines
dc.subjectPhenotype-specific treatment
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleFor which infants with viral bronchiolitis could it be deemed appropriate to use albuterol, at least on a therapeutic trial basis?
dc.typeartículo
dc.volumen49
sipa.codpersvinculados113247
sipa.trazabilidadORCID;2024-01-15
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vprasanna,+AEI_12-49-153.pdf
Size:
387.16 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas